---
title: "HIV charities lament NICE snub for Gilead’s twice-yearly lenacapavir"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/298763671.md"
description: "A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser."
datetime: "2026-09-11T13:10:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/298763671.md)
  - [en](https://longbridge.com/en/news/298763671.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/298763671.md)
generator: "portal-rs"
---

# HIV charities lament NICE snub for Gilead’s twice-yearly lenacapavir

A required part of this site couldn’t load. This may be due to a browser extension, network issues, or browser settings. Please check your connection, disable any ad blockers, or try using a different browser.

### Related Stocks

- [GILD.US](https://longbridge.com/en/quote/GILD.US.md)
- [GIS.DE](https://longbridge.com/en/quote/GIS.DE.md)

## Related News & Research

- [Should Gilead Sciences (GILD) Reconsider Its Global HIV Case After This PAHO Deal?](https://longbridge.com/en/news/299152634.md)
- [Gilead and PAHO agree to expedite lenacapavir access for HIV prevention](https://longbridge.com/en/news/299162054.md)
- [We got a new clue about Xbox's ad ambitions](https://longbridge.com/en/news/299178240.md)
- [GILD: Strong HIV growth, new launches, and oncology advances drive portfolio momentum](https://longbridge.com/en/news/299078477.md)
- [Gilead Sciences Sees Sunlenca Launch Fueling Long-Term HIV Growth](https://longbridge.com/en/news/298621247.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**